Skip to main content
Glaucoma Australia
April 2022

Applications for the annual Glaucoma Australia ‘Quinlivan’ Research Grants are now open until 5pm (AEST) 31 May 2022, with the successful recipient(s) being announced on World Sight Day, Thursday 13 October 2022.

Image of scientist looking in microscope in lab

“We are very proud to continue to fund high quality Australian glaucoma research that supports our mission to prevent sight loss by increasing early detection and improving treatment adherence” said Glaucoma Australia CEO Annie Gibbins.

The William A Quinlivan Research Fund was established in 2006 by the late Mr Marcus Quinlivan in honour of his father. Since the fund was created, Glaucoma Australia has committed over $1.5 million towards glaucoma research which improves quality of life for people diagnosed with glaucoma through better detection, treatment, and monitoring.

Glaucoma Australia will invest up to $200,000 in this funding round and anticipates between 1 and 4 grants will be awarded. All projects are to be completed within 3 years of grant allocation and seed fund grants can be used to apply for further funding with NHMRC or other agencies.

Glaucoma Australia is committed to supporting research which focuses on the following four domains:

  1. Increasing the rate and reliability of early detection of glaucoma
  2. Improving the treatment and care experience
  3. Improving the quality and experience of monitoring glaucoma progression
  4. Providing management tools to improve the quality of life for people with glaucoma

The Glaucoma Australia ‘Quinlivan’ Research Grants are awarded following rigorous evaluation, based largely on the National Health and Medical Research Council (NHMRC) process, along with peer review, to ensure that the successful applicants meet the highest standards. Submissions are reviewed by the Glaucoma Australia Independent Research Panel consisting of internationally recognised experts in glaucoma research including the fields of Ophthalmology, Optometry and Pharmacy.  

Applications available here.